Biotech Values

[DewDiligence]

ENTA 1-year look-back (share price movements in Dec 2013/Jan 2014):

An ENTA sell-off in Dec 2013 was directly attributable to the release of GILD’s data from the three ‘ION’ studies on 12/18/13 (#msg-95076667). ENTA’s share price recovered gradually and then received a major boost on 1/31/14, when ABBV/ENTA released phase-3 data from four studies (including TURQUOISE-2 in cirrhotic patients) and it became evident that ABBV/ENTA's overall phase-3 dataset was clinically equivalent to GILD’s (#msg-96618696).

(See #msg-96696670 for a summary of both companies’ data in tabular form.)